指南与共识头颈部肿瘤放疗

头颈部鳞癌原发肿瘤CTV-P勾画国际共识指南

Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines.
指南 / 共识 · Radiother Oncol · 2017-11-24

该共识由AIRO、CACA、DAHANCA、EORTC等多国学术组织共同制定,针对喉、下咽、口咽及口腔鳞癌,将DAHANCA的几何外扩理念与头颈解剖分区知识结合,经全球专家讨论形成原发肿瘤CTV-P1和CTV-P2两层靶区勾画建议,分别对应高剂量和低剂量处方,旨在减少勾画差异并促进多中心临床试验。

要点

  • 原发肿瘤设CTV-P1和CTV-P2两层靶区,分别对应高剂量和低剂量处方。
  • 共识整合DAHANCA几何外扩与头颈解剖分区两种思路形成勾画框架。
  • 覆盖喉、下咽、口咽、口腔各解剖亚区及各T分期。

核心结论

  • 共识提出原发肿瘤CTV-P1和CTV-P2两层靶区,分别对应高剂量和低剂量处方,以统一头颈鳞癌原发灶勾画。

研究设计与样本

  • 由AIRO、CACA、DAHANCA、EORTC等多国学术组织共同制定,对DAHANCA几何外扩提案按各解剖亚区和T分期结合解剖知识全面审阅修订,并经欧亚澳美专家讨论达成全球共识。

主要发现

  • 对喉、下咽、口咽和口腔各解剖部位及各T分期,将DAHANCA的几何CTV勾画概念融入解剖学知识进行修订。
  • 共识建议原发肿瘤设CTV-P1和CTV-P2两个靶区,分别对应高剂量和低剂量处方。

关键数值与推荐

  • 原发肿瘤设CTV-P1(高肿瘤负荷,高剂量处方)和CTV-P2(较低肿瘤负荷,较低剂量处方)两层靶区。

临床怎么用

  • 在日常放疗实践中实施该指南,有望减少临床医生间的治疗差异,便于开展多中心临床试验,并改善头颈癌患者诊疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Few studies have reported large inter-observer variations in target volume selection and delineation in patients treated with radiotherapy for head and neck squamous cell carcinoma. Consensus guidelines have been published for the neck nodes (see Grégoire et al., 2003, 2014), but such recommendations are lacking for primary tumour delineation. For the latter, two main schools of thoughts are prevailing, one based on geometric expansion of the Gross Tumour Volume (GTV) as promoted by DAHANCA, and the other one based on anatomical expansion of the GTV using compartmentalization of head and neck anatomy. METHOD: For each anatomic location within the larynx, hypopharynx, oropharynx and oral cavity, and for each T-stage, the DAHANCA proposal has been comprehensively reviewed and edited to include anatomic knowledge into the geometric Clinical Target Volume (CTV) delineation concept. A first proposal was put forward by the leading authors of this publication (VG and CG) and discussed with opinion leaders in head and neck radiation oncology from Europe, Asia, Australia/New Zealand, North America and South America to reach a worldwide consensus. RESULTS: This consensus proposes two CTVs for the primary tumour, the so called CTV-P1 and CVT-P2, corresponding to a high and lower tumour burden, and which should be associated with a high and a lower dose prescription, respectively. CONCLUSION: Implementation of these guidelines in the daily practice of radiation oncology should contribute to reduce treatment variations from clinicians to clinicians, facilitate the conduct of multi-institutional clinical trials, and contribute to improved care of patients with head and neck carcinoma.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Grégoire V, Evans M, Le QT, et al. Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. Radiother Oncol. 2017. PMID: 29180076. doi:10.1016/j.radonc.2017.10.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。